Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: GlobeNewswire
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with locally advanced or metastatic solid tumors of the lung. “Cytokine therapy holds significant potential for the treatment of solid tumors but its utility has been limited by a lack of safe and effective delivery options,” said David Chien, M.D., Senior Vice President of Clinical Development at Krystal Biotech. “Cytokine delivery via inhalation is a first-of-its-kind therapeutic approach made possible by the unique attributes of Krystal’s HSV-1-based vector platform. Together with intratumor
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Why Krystal Biotech (KRYS) Might Surprise This Earnings Season [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingGlobeNewswire
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024GlobeNewswire
- Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 11/6/23 - Miss
KRYS
Sec Filings
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- 3/11/24 - Form 4
- KRYS's page on the SEC website